Sign in Subscribe
COVID-19

COVID-19 Vaccine Efficacy in Kidney Transplant Recipients

Strategic Insights

— 1 min read

A recent study conducted in Italy has investigated the humoral response trajectories and determinants of breakthrough infection in kidney transplant recipients after SARS-CoV-2 vaccination. The research, published in the journal Vaccines, shed light on the limited humoral response to SARS-CoV-2 vaccination in infection-naive patients but improved with booster dosing. The study also found that immunosuppressive regimens, including mTOR inhibitors, may influence the immune response and protect against breakthrough infection.

Key Takeaways:

  • The study evaluated the humoral response trajectories and determinants of breakthrough infection in 326 kidney transplant recipients after SARS-CoV-2 vaccination.
  • The results showed that antibodies were detectable in 89% of patients with previous COVID-19 disease or asymptomatic SARS-CoV-2 infection at baseline, but were negligible in infection-naive patients.
  • The seropositivity increased after vaccination and booster in infection-naive patients, reaching 78% at 12 months.
  • The study concluded that the humoral response to SARS-CoV-2 vaccination is limited in infection-naive patients but improved with booster dosing.
  • The research also found that immunosuppressive regimens, including mTOR inhibitors, may influence the immune response and protect against breakthrough infection.

Statistics:

  • 326 kidney transplant recipients were enrolled in the study.
  • 189 patients with complete time-point data were included in the longitudinal analysis.
  • 89% of patients with previous COVID-19 disease or asymptomatic SARS-CoV-2 infection had detectable antibodies at baseline.
  • 78% of infection-naive patients had seropositivity after vaccination and booster at 12 months.
  • The study found a decrease in antibody titers by 5% per year in kidney transplant recipients.

Sources:

  • Long-term Immuno-Response and Risk of Breakthrough Infection After SARS-CoV-2 Vaccination in Kidney Transplantation. Vaccines, 2025,13(6):566. (Vaccines - http://www.mdpi.com/journal/vaccines).
  • Medical Letter on the CDC & FDA. July 13, 2025; p 169.

Read more